Building on positive data from an earlier study, Allrock Bio has dosed the first patients in a small clinical trial testing ROC-101, its oral treatment candidate for pulmonary hypertension (PH). The open-label Phase 2a ROCSTAR study (NCT07175038) is recruiting patients across the U.S., Canada, and Europe — including…